Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATION Study: Oral Semaglutide and Vascular Inflammation in Japanese Patients with Type 2 Diabetes
jRCTs071220027Recruiting
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms). Primary endpoint: Change in vascular inflammation (FDG-PET/CT TBR) at 6 months. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on jRCTs071220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220027.